CFDs are complex instruments. You can lose your money rapidly due to leverage. Please ensure you understand how this product works and whether you can afford to take the high risk of losing money. CFDs are complex instruments. You can lose your money rapidly due to leverage. Please ensure you understand how this product works and whether you can afford to take the high risk of losing money.

UK stock preview: Rolls-Royce, Shell, Avacta

Here are three LSE mainboard stocks to watch this week.

  • Rolls-Royce shares are up 1.5% on Monday morning (06 September 2021)
  • Avacta share price jumped up nearly 3% as it made new appointments to its Scientific Advisory Board
  • Shell shares rose 0.6% on the confirmation of 2Q 2021’s interim dividend rate
  • Keen to trade these three FTSE 100 stocks? Open an account with us to get started.

Rolls-Royce (LON: RR)

Rolls-Royce Holdings appointed UBS as its joint corporate broker with immediate effect from last Thursday.

UBS will work alongside Morgan Stanley, the Company's existing corporate broker. This means RR’s other long-time house broker Jefferies is out.

This move confirmed earlier reports that the aviation engineer was reportedly seeking to replace both Jefferies and Morgan Stanley as part of a plan to rebuild its market valuation.

The FTSE 100 company was said to have invited other investment firms to pitch for the position.

Observers said that one of the first things on UBS’ expected agenda would be to revive investor interest in the Rolls-Royce stock, which has been wiped out by over 50% since the start of the Covid-19 pandemic.

Avacta (LON: AVCT)

Avacta Group has announced new appointments to its Scientific Advisory Board (SAB).

The SAB provides the biotech company’s Therapeutics Division with scientific and clinical advice to support its drug development decision making and pipeline strategy.

The appointments are expected to help further Avacta’s transition into a clinical stage company.

“The wealth of knowledge these individuals will bring, both scientific and clinical, as well as their strategic and commercial insight, will be a major benefit to us as we expand our preclinical programmes and take the next drug candidates into the clinic,” said Dr Alastair Smith, Chief Executive Officer of Avacta Group.

The three new members of the SAB are Professor James Spicer MB., BA., PhD., FRCP, Professor Krishnan Komanduri, MD, and Dr Stéphane Champiat MD, PhD.

What’s your view on these FTSE 100 Index stocks?

Go short and long with CFDs on Rolls-Royce, Shell, Avacta and 16,000+ shares with our award-winning trading platform.* Learn more about trading shares with us, or open an account to get started today.

* Best trading platform as awarded at the ADVFN International Financial Awards and Professional Trader Awards 2019

Read more: Top 5 UK stocks to buy in September 2021

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.